Compare OCFC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | OGN |
|---|---|---|
| Founded | 1902 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | OCFC | OGN |
|---|---|---|
| Price | $18.90 | $13.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $21.67 | $11.40 |
| AVG Volume (30 Days) | 967.2K | ★ 2.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.24% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.27 | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $47.51 | $0.45 |
| Revenue Next Year | $21.97 | $1.67 |
| P/E Ratio | $69.93 | ★ $14.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.05 | $5.69 |
| 52 Week High | $20.61 | $13.77 |
| Indicator | OCFC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 72.77 |
| Support Level | $17.31 | $13.46 |
| Resistance Level | $19.35 | N/A |
| Average True Range (ATR) | 0.31 | 0.03 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 20.18 | 91.67 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.